This cross collaboration of Johnson & Johnson Family of Diabetes Companies (Janssen, LifeScan, Animas® and The Johnson & Johnson Institute) ensures the Company’s ongoing commitment to serve the needs of people with diabetes across the continuum of care. Today, Johnson & Johnson Family of Diabetes Companies touch more than 10 million people with diabetes worldwide.
Animas®, a maker of insulin pumps, is dedicated to making diabetes management easier through product innovation, exceptional customer support, and customised education programs.
We strive to improve the quality of life of patients and reduce the long-term morbidity of the disease. With headquarters located in Chesterbrook, Pennsylvania, Animas® has a distribution presence in 20 countries worldwide. Animas® is committed to advancing diabetes management to address unmet patient needs.
LifeScan has a 30-year heritage in this disease area and is a leading provider of self-monitoring blood glucose (SMBG) meter systems. The company, which was founded in 1981,currently employs over 2,500 people, has a presence in more than 74 countries worldwide and is continuing to expand in Europe. LifeScan’s worldwide HQ is located in Wayne, Pennsylvania and the European base is located in Zug, Switzerland.
Since its inception, LifeScan has been committed to helping people with diabetes to live a life without limits. The flagship product line at LifeScan is a complete range of blood glucose meters that has been utilised by many hundreds of thousands of people with diabetes and is currently recommended by doctors, pharmacists and diabetes health professionals from all four corners of the globe. Blood glucose monitoring products provide a complete system for measuring and delivering test results - all designed to help patients with an integrated approach to monitoring their diabetes.
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases.
In our business there’s no time to waste. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.
Janssen has an enduring commitment to researching the prevention and treatment of metabolic diseases, such as Type 2 diabetes. Our aim is to develop innovative healthcare solutions that will significantly improve the outcome for patients. We are building a comprehensive approach to diabetes care and have developed an insulin-independent way to improve glycaemic control in adult patients with Type 2 diabetes.
Johnson & Johnson Institute
The Johnson & Johnson Institute adopts an innovative approach to professional diabetes education. The Institute is a collaborative learning environment, comprising of an online community and global professional education activities and facilities. The purpose of the Institute is for healthcare professionals to learn from the faculty and from each other, in order to transform diabetes care.
The Johnson & Johnson Institute covers a wide curriculum of educational topics, specific to each country or region. Key topic areas for education are identified through working with leading diabetes organisations, public health institutes and health care professionals. In general, courses offered will cover training on innovative practice models and modern diabetes technologies, the implementation of proven guidelines/existing diabetes tools to solve patient problems and strategies for behaviour change.
The Johnson & Johnson Institute was founded in 2007 and offers interactive learning opportunities through various digital platforms including www.jjdi.com.
Mission and values.
The Johnson & Johnson Institute’s mission is to improve the paradigm of diabetes care-transforming the intent from managing diabetes to mastering diabetes through the provision of advanced training in diabetes care for healthcare professionals.